Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Mayo Clinic, Rochester, MN, United States

Survival: 12.3 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Rochester, MN
Hospital: Mayo Clinic
Journal: Link
Date: 8/2012

This phase 2 study involved previously untreated metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 42 patients with a median age of 57 years and 57.1% male. Group B had 51 patients with a median age of 57 years and 56.9% male.

Patients in group A were treated with the chemotherapy agent temozolomide and the biologic therapy agent bevacizumab.

Patients in group B were treated with the chemotherapy agents nab-paclitaxel and carboplatin, as well as the biologic therapy agent bevacizumab.

There were two treatment-related deaths due to bone marrow suppression and disease progression reported for groupA. Grade 3-4 leukopenia, neutropenia, vomiting, and fatigue were also reported.

The most severe toxicities reported for group B were of grade 4. Grade 3-4 toxicities included neutropenia, leukopenia, thrombocytopenia, anemia, fatigue, and thrombosis.

The median overall survival rates for groups A and B were 12.3 and 13.9 months, respectively.

Correspondence: Dr. Lisa A. Kottschade; email:

E-mail to a Friend Email Physician More Information